We observed efficient and selective depletion of Malat1 lncRNA in PSMA+/+ cancer cells with almost no activity in PSMA−/− cells for AS02-md and ASO3-bmd conjugates with PSMA ligand MA-257 at concentrations from 100 nM to 10 μM, which confirms the promise of mesyl and busyl phosphoramidate ASO modifications for the targeted RNA therapy. The gene discussed is FOLH1; the disease is cancer.